Windlas Biotech commissions injectable facility to manufacture small volume parenteral products

02 Apr 2024 Evaluate

Windlas Biotech has commissioned its state-of-the-art injectable facility for manufacturing of Small Volume Parenteral products, built to meet international cGMP standards. The company has received manufacturing license from the Drug Controlling & Licensing Authority of Uttarakhand after joint inspection conducted by Central Drugs Standard Control Organisation and State Licensing Authority of Uttarakhand. 

The facility has initiated manufacturing of commercial batches and it expects to introduce several new products over the course of Financial Year 2025. This milestone marks company’s continued foray in development and manufacturing of complex dosage forms like Ampoules, Liquid Vials and Lyophilized Vials thereby extending its product portfolio to critical care and other specialized therapeutic segments. This Injectable plant shall cater to all three of its business verticals: CDMO, Trade Generics & Institutional, and Exports. 

Windlas Biotech provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world. 


Windlas Biotech Share Price

545.95 -3.10 (-0.56%)
30-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1502.30
Dr. Reddys Lab 6198.90
Cipla 1402.20
Zydus Lifesciences 957.00
Lupin 1645.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.